Literature DB >> 31850119

Psychological Impact of Melanoma, How to Detect, Support and Help.

Aleksandra Vojvodic1, Tatjana Vlaskovic-Jovicevic2, Petar Vojvodic2, Jovana Vojvodic2, Mohamad Goldust3, Zorica Peric-Hajzler4, Dusica Matovic4, Goran Sijan5, Nenad Stepic5, Van Thuong Nguyen6, Michael Tirant3, Uwe Wollina7, Torello Lotti8, Massimo Fioranelli9.   

Abstract

Incidence of melanoma is increasing every year. A few years ago, we could not speak about long term survivors with melanoma. Chemotherapy did not give a good effect in the past. Metastasis occurred very rapidly, and the progression of melanoma was very fast. But now, with new forms of therapy, especially immunotherapy and target therapy, for the first time, we have long-time survivors. For the prognosis of melanoma, the most important is the stage in which melanoma is detected. For all dermatologists, it is very important to be aware of the psychological impact of melanoma on patients. Dermatologists should recognise psychological disorders. Several different scales can be used for the detection of depression and anxiety - some of them are completed by researchers, some of them are completed by patients, and also, we have combined scales. The need for adequate social and family support as well as psychological help to achieve better coping with illness is necessary. Learning techniques to overcome fear and stress would help in better functioning of all affected, regardless of the stage of the disease. The most severe cases of anxiety and depression, in addition to psychotherapeutic interventions, should also be considered medication therapy. Copyright:
© 2019 Aleksandra Vojvodic, Tatjana Vlaskovic-Jovicevic, Petar Vojvodic, Jovana Vojvodic, Mohamad Goldust, Zorica Peric-Hajzler, Dusica Matovic, Goran Sijan, Nenad Stepic, Van Thuong Nguyen, Michael Tirant, Uwe Wollina, Torello Lotti, Massimo Fioranelli.

Entities:  

Keywords:  Anxiety; Depression; Melanoma; Psychology

Year:  2019        PMID: 31850119      PMCID: PMC6910785          DOI: 10.3889/oamjms.2019.770

Source DB:  PubMed          Journal:  Open Access Maced J Med Sci        ISSN: 1857-9655


Introduction

Incidence of melanoma is increasing every year. There are different sources with different data, very controversial, but it is evident increasing in incidence, especially in men over the age of 60. It is more frequent in young girls than in young men probably because of the use of the sunbeds. But, in Australia, New Zealand, the USA, North and Eastern Europe incidence is the highest. The fair-skinned, overexposed white population is in the greatest risk. A few years ago, we could not speak about long term survivors with melanoma. Chemotherapy did not give a good effect in the past. Metastasis occurred very rapidly, and the progression of melanoma was very fast. In young people, progression was even more aggressive. Living with melanoma was not considered and occurred very rarely. But now, with new forms of therapy, especially immunotherapy and target therapy, for the first time, we have long-time survivors. For the prognosis of melanoma, the most important is the stage in which melanoma is detected. If it is detected in the IA stage 5-years survival is 97%, but if it is detected in the IV stage 5-years survival is only 15%. Living with melanoma is not easy, even if it is detected in the first stage. Follow up procedures every 3 or 6 months, laboratory testing, different examinations, surgery interventions, skin checking and other follow up procedures are very hard for all patients. Fear of the progression of the disease is always present, even if it is diagnosed in the IA stage. Sometimes, but not so frequently, depression is also detected. We can mostly detect depressive symptoms, or minor depressive disorder and very rarely major depressive disorder.

The most frequent psychological disorders and scales

For all dermatologists, it is very important to be aware of the psychological impact of melanoma on patients. Dermatologists should recognise psychological disorders. Depressed mood, loss of interest/pleasure, significant weight loss or weight gain without trying to, insomnia or hypersomnia, psychomotor agitation/retardation, daily fatigue or loss of energy, feelings of worthlessness or excessive guilt, inability or difficulty with thinking, concentrating, and making decisions, suicidal thoughts, plans to commit suicide, or a suicide attempt. Sometimes, very rarely, we can detect symptoms of psychosis-delusions or hallucinations. For the diagnosis of major depressive disorders, it is necessary coexistence of 5-9 symptoms that last at least 2 weeks. For diagnosis of minor depressive disorder coexistence of 2 / 4 symptoms that last at least 2 weeks are necessary. Dysthymic disorder is different, and it is characterised by the depressive mood that lasts longer than 2 years, with mostly 2-6 symptoms. Several different scales can be used for detection of depression – some of them are completed by researchers, some of them are completed by patients, and also, we have combined scales. Some of the scales completed by researchers are the Hamilton Depression Rating Scale, Montgomery-Åsberg Depression Rating Scale, Raskin Depression Rating Scale. But for dermatologists and screening programs, the most important are scales completed by patients. The Beck Depression Inventory is a scale that is in use very frequently. It consists of a 21-question, and it is self-report inventory that covers different symptoms that are present in depression such as fatigue, lack of interest in sex, weight loss, feelings of guilt, hopelessness, etc. The scale is completed by patients to identify the presence and severity of symptoms consistent with the DSM-IV diagnostic criteria. The next very frequently used self-reported questionnaire is The Patient Health Questionnaire (PHQ). The Patient Health Questionnaire-9 (PHQ-9) is a self-reported, 9-question version of the Primary Care Evaluation of Mental Disorders and it is very useful for quick screening. The Patient Health Questionnaire-2 (PHQ-2) is a shorter version of the PHQ-9 with only two questions to assess the presence of a depressed mood and a loss of interest or pleasure in routine activities. If it is detected, further testing is needed. Other scales that can be used are The Geriatric Depression Scale (GDS), Zung Self-Rating Depression Scale , The Clinically Useful Depression Outcome Scale (CUDOS), The Inventory of Depressive Symptomatology (IDS), The Mood and Feelings Questionnaire (MFQ), The Quick Inventory of Depressive Symptoms (QIDS), The Jacobson Joy Inventory (JJI)-Research in process-Banner University Medical Center, The Positive Health Questionnaire (PHQ) Research in process-Banner University Medical Center, etc. Anxiety is very frequent, and it can be detected in almost all patients with melanoma. It is a feeling of apprehension caused by anticipation of an ill-defined threat or danger that is not based. Components of anxiety are emotional, cognitive anticipation (memory), behavioural and somatic. There are different scales for measuring level of anxiety – Brief fear negative evaluation scale / BFNE, depression anxiety stress scales-DASS-21, Generalized anxiety disorder questionnaire IV – GADQ-IV, generalized anxiety disorder-GAD 7 (Table 1), Hamilton Anxiety rating scale – HARS, Leibowitz social anxiety scale – LSAS, overall anxiety severity and impairment scale (OASIS), hospital anxiety and depression scale – HADS, patient health questionnaire 4 – PHQ-4, Penn state worry questionnaire – PSWQ, etc.
Table 1

Depression and symptoms

Major depressive disorderMinor depressive disorderDysthymiaSymptoms 1. depressed mood 2. loss of interest/pleasure 3. significant weight loss or weight gain without trying to 4. insomnia or hypersomnia 5. psychomotor agitation/retardation 6. daily fatigue or loss of energy 7. feelings of worthlessness or excessive guilty 8. inability or difficulty with thinking, concentrating and making decisions 9. suicidal thoughts, plans to commit suicide, or a suicide attempt
2 weeks duration2 weeks duration2 years duration
Depressed mood or loss of interestDepressed mood or loss of interestDepressed mood
5 of 9 Symptoms2-4 of 9 Symptoms2-6 Symptoms
Depression and symptoms For dermatologists, for fast screening, GAD-7 and BAI are very useful. They are self-reported questionnaires, and very fast, and with a high-quality dermatologist can detect the level of anxiety (Table 2).
Table 2

Generalized anxiety disorder- GAD 7

Over the last 2 weeks, how often have you been bothered by the following problems?Not at all sureSeveral daysOver half the daysNearly every day
1. Feeling nervous, anxious, or on edge0123
2. Not being able to stop or control worrying0123
3. Worrying too much about different things0123
4. Trouble relaxing0123
5. Being so restless that it’s hard to sit still0123
6. Becoming easily annoyed or irritable0123
7. Feeling afraid as if something awful might happen0123
Add the score for each column
Total Score (add your column scores) =
Generalized anxiety disorder- GAD 7 If dermatologist detects any level of anxiety or some of depressive symptoms, it is necessary to advise patient to visit psychologist, psychotherapist or psychiatrist. How patient will accept the disease depends very much on their mechanisms of defence. Also, support and help are necessary, the first from the family members, friends, colleges, but also from doctors/ dermatologists, and at the and professional help from psychiatrists, psychologists and psychotherapists. There are described mostly three general theoretical coping styles in the psycho-oncology literature: 1) Active-behavioral coping – this coping style refers to overt behavioural attempts to deal directly with cancer and its effects; 2) Active cognitive coping, this coping style includes one’s attitudes, beliefs, and thoughts about cancer; 3) Avoidance coping, this coping style refers to attempts to actively avoid the problem or indirectly reduce emotional tension through the use of distraction. All these mechanisms of coping are useful but not equally. In conclusion, the need for adequate social and family support as well as psychological help in order to achieve better coping with illness is necessary. Learning techniques to overcome fear and stress would help in better functioning of all affected, regardless of the stage of the disease. The most severe cases of anxiety and depression, in addition to psychotherapeutic interventions should also be considered medication therapy. The need for a multidisciplinary team that would be involved in monitoring the patient from the moment of the establishing the diagnosis of melanoma is of exceptional importance and include dermatologist, surgeon, radiotherapist, neurologist and psychiatrist, psychologist, psychotherapist.
  15 in total

1.  Treatment with β-blockers and reduced disease progression in patients with thick melanoma.

Authors:  Vincenzo De Giorgi; Marta Grazzini; Sara Gandini; Silvia Benemei; Torello Lotti; Niccolò Marchionni; Pierangelo Geppetti
Journal:  Arch Intern Med       Date:  2011-04-25

2.  Cutaneous melanoma: how to improve the quality of diagnosis and treatment - a regional experience.

Authors:  Anastasiya Atanasova Chokoeva; Georgi Tchernev; Uwe Wollina; Torello Lotti
Journal:  Dermatol Ther       Date:  2015-08-17       Impact factor: 2.851

3.  Mental health: a world of depression.

Authors:  Kerri Smith
Journal:  Nature       Date:  2014-11-13       Impact factor: 49.962

4.  Completion dissection or observation for sentinel-node metastasis in melanoma.

Authors:  Massimo Fioranelli; Maria Grazia Roccia; Carlo Pastore; Carolina Jahaira Aracena; Torello Lotti
Journal:  Dermatol Ther       Date:  2017-08-24       Impact factor: 2.851

5.  Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial.

Authors:  Mbathio Dieng; Phyllis N Butow; Daniel S J Costa; Rachael L Morton; Scott W Menzies; Shab Mireskandari; Stephanie Tesson; Graham J Mann; Anne E Cust; Nadine A Kasparian
Journal:  J Clin Oncol       Date:  2016-10-28       Impact factor: 44.544

6.  Long-Term Quality of Life of Melanoma Survivors Is Comparable to that of the General Population.

Authors:  Pia J Heino; Pia H Mylläri; Tiina A Jahkola; Harri Sintonen; Minna-Liisa Luoma; Pirjo Räsänen; Risto P Roine
Journal:  Anticancer Res       Date:  2019-05       Impact factor: 2.480

7.  Controversial issues on melanoma.

Authors:  Torello Lotti; Nicola Bruscino; Jana Hercogova; Vincenzo de Giorgi
Journal:  Dermatol Ther       Date:  2012 Sep-Oct       Impact factor: 2.851

8.  Melanoma diagnosis: traumatic impact of the event on the patient.

Authors:  Eleonora Campolmi; Margherita Riccio; Bernardo Carli; Giovanni Bacci; Maria S Pino; Sara Fortunato; Susanna Gunnella; Luisa Fioretto; Lorenzo Borgognoni; Nicola Pimpinelli
Journal:  Ital J Dermatol Venerol       Date:  2019-06-12

Review 9.  Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors.

Authors:  Anne Rogiers; Annelies Boekhout; Julia K Schwarze; Gil Awada; Christian U Blank; Bart Neyns
Journal:  J Oncol       Date:  2019-04-28       Impact factor: 4.375

10.  An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.

Authors:  Aine O'Reilly; Peta Hughes; Jasmine Mann; Zhuangming Lai; Jhia Jiat Teh; Emma Mclean; Kim Edmonds; Karla Lingard; Dharmisha Chauhan; Joanna Lynch; Lewis Au; Aileen Ludlow; Natalie Pattison; Theresa Wiseman; Samra Turajlic; Martin Gore; James Larkin; Olga Husson
Journal:  Support Care Cancer       Date:  2019-05-14       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.